Nivalis Therapeutics, Inc. (NASDAQ:ALPN) has received a consensus recommendation of “Hold” from the nine brokerages that are currently covering the stock, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell rating, five have given a hold rating and two have issued a buy rating on the company. The average 1 year price objective among analysts that have covered the stock in the last year is $6.35.
ALPN has been the subject of several recent analyst reports. Zacks Investment Research cut shares of Nivalis Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Thursday, October 26th. ValuEngine upgraded shares of Nivalis Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, July 27th. Finally, Ladenburg Thalmann Financial Services initiated coverage on shares of Nivalis Therapeutics in a research report on Thursday, July 27th. They set a “buy” rating and a $17.00 price objective for the company.
A hedge fund recently bought a new stake in Nivalis Therapeutics stock. Sowell Financial Services LLC purchased a new position in Nivalis Therapeutics, Inc. (NASDAQ:ALPN) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 15,714 shares of the biotechnology company’s stock, valued at approximately $162,000. Sowell Financial Services LLC owned 0.40% of Nivalis Therapeutics at the end of the most recent quarter.
Nivalis Therapeutics (ALPN) traded up $0.27 on Thursday, hitting $10.77. 4,566 shares of the stock traded hands, compared to its average volume of 56,802. Nivalis Therapeutics has a 52 week low of $7.20 and a 52 week high of $25.84. The company has a quick ratio of 32.38, a current ratio of 32.38 and a debt-to-equity ratio of 0.05.
About Nivalis Therapeutics
Nivalis Therapeutics, Inc is a pharmaceutical company. The Company focuses on the discovery and development of product candidates for patients with cystic fibrosis (CF). Its drug candidate portfolio consists of multiple compounds, which are designed for oral, intravenous (IV) or inhaled administration.
Receive News & Ratings for Nivalis Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nivalis Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.